Jessica Chutter

Vice Chair and Chair of Biotechnology Investment Banking

Jessica Chutter picture

Jessica Chutter

Morgan Stanley

Vice Chair and Chair of Biotechnology Investment Banking

Jessica Chutter is a Vice Chair and Chair of Biotechnology Investment Banking at Morgan Stanley. During Ms. Chutter’s 30+ year career of building Morgan Stanley’s Biotechnology Franchise, she has been responsible for $70Bn of capital raising and $85Bn of strategic transactions. Jessica is focused on company-building, examples of which include raising $3Bn for Moderna (4 offerings), $2.4Bn for GW (6 offerings) and $2.2Bn for BeiGene (5 offerings). Jessica has led 18 IPOs totaling ~$4Bn, including those for Canadian-based Repare Therapeutics and Fusion Pharmaceuticals. Strategic transactions include advising Agios in its Oncology Business sale to Servier, Galapagos in its $5.1Bn transformative partnership with Gilead and Company sales of Clementia, Cubist, Pharmasset and Elan. She has also been involved in the creation of a new asset class involving royalty-backed debt (PhaRMA) where over $24Bn has been raised.

Ms. Chutter has a BA in Commerce/Honours Economics from McGill University and an MBA from Harvard Business School. Ms. Chutter is a director of Toronto Innovation Acceleration Partners and the Board of Trustees of SickKids as well as a member of the McGill’s Toronto Advisory Board. She resides in Toronto with her husband, Derek Berghuis, and has three children – Andrew, Jennifer and Kevin.